Loading
Lung Cancer Research Studies / Lung Cancer Treatments and Mutations · Journal article
Cancers · August 17, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes current understanding of brain metastases management in EGFR-mutant NSCLC, highlighting unmet needs and clinical challenges including therapy sequencing, resistance, and blood–brain barrier penetration. It does not present original efficacy data or comparative outcomes, but rather offers a structured overview of the clinical landscape and treatment considerations to guide decision-making.
Narrative review. Patients with brain metastases and EGFR-mutant non-small-cell lung cancer.
Brain metastases are a leading cause of morbidity and mortality in EGFR-mutant NSCLC patients. Local treatments such as radiotherapy are effective but carry risks of long-term neurological side effects. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life.
Brain metastases are a leading cause of morbidity and mortality in EGFR-mutant NSCLC patients. Local treatments such as radiotherapy are effective but carry risks of long-term neurological side effects.
This review provides clinicians with a comprehensive framework for understanding the complexity of CNS disease in EGFR-mutant NSCLC, emphasizing the need for individualized, multidisciplinary approaches that balance treatment efficacy with quality of life and incorporate patient perspectives.
A narrative review summarizing current management approaches, challenges, and clinical considerations for brain metastases in EGFR-mutant NSCLC without reporting original efficacy data or comparative outcomes.
As stated by the source record.
This review provides clinicians with a comprehensive framework for understanding the complexity of CNS disease in EGFR-mutant NSCLC, emphasizing the need for individualized, multidisciplinary approaches that balance treatment efficacy with quality of life and incorporate patient perspectives.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Brain metastases represent a major clinical challenge in the management of non-small-cell lung cancer, particularly in patients with epidermal growth factor receptor mutations, constituting a leading cause of morbidity and mortality. In recent years, significant advancements have been made in both local therapies and systemic treatments. Nevertheless, managing central nervous system disease remains complex, encompassing challenges such as optimal therapy sequencing, resistance mechanisms, oligoprogression, the role of the blood–brain barrier, diagnostic strategies, and the influence of the brain tumor microenvironment. Despite advances, brain metastases in non-small-cell lung cancer remain an unmet need. Local treatments like radiotherapy are effective but carry risks of long-term neurological side effects, while the number and burden of brain metastases remain key prognostic factors. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life. With the extension of survival afforded by systemic therapies, optimizing the balance between treatment efficacy and quality of life has become critical. Integrating patient perspectives is essential in navigating these complex clinical decisions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.